

Abacus Medicine Pharma Services and Gen.Orph sign partnership agreement for the exclusive distribution of Miglustat Gen.Orph in Austria

Abacus Medicine Pharma Services (AMPS) and Gen.Orph are proud to announce the signing of a partnership agreement for the exclusive marketing and distribution of Miglustat Gen.Orph in Austria.

Miglustat Gen.Orph 100 mg hard capsules is indicated for the oral treatment of mild to moderate type 1 Gaucher disease in adult patients. It must only be used to treat patients for whom enzyme replacement therapy is not an option. In addition, Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.

Miglustat Gen.Orph has obtained reimbursement for both indications and is positioned in the yellow-box according to the Erstattungskodex (list of reimbursed pharmaceutical products).

Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains, "This is an exciting opportunity for both companies as it unlocks new geographies for Gen.Orph making the alternative treatment option available to patients and prescribers."

Etienne Jacob, CEO and Founder of Gen.Orph continues, "Due to the low prevalence of lysosomal disorders, the launch of Miglustat Gen.Orph in Austria was unlikely to happen. However, working in partnership with Abacus Medicine Pharma Services, their innovative approach has enabled us to respond to the market needs of patients and prescribers by delivering choice via the first dual-indication Miglustat therapy into the Austrian market."

Product information:

- Miglustat Gen.Orph 100mg hard capsules 84 pieces
- PhZNR 5512466
- Distribution is via the full range of pharmaceutical wholesalers

Abacus Medicine Pharma Services (AMPS) is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines. 1,100 employees service thousands of customers in Europe and the rest of the world. With a customised ERP system, a bespoke global distribution centre and a leadership team with decades of experience, AMPS is evolving into the next-generation healthcare and pharma services company by combining the infrastructure and skills at Abacus Medicine with the experience and expertise within AMPS.

Gen.Orph is a developer of generic orphan drugs designed to treat rare diseases. The company's drugs offer patients and medical teams worldwide generic orphan medicines that are affordable and effective at curing rare diseases as well as drugs that are neglected by the pharmaceutical industry despite their medical efficiency, enabling patients to get treatment for rare diseases at affordable costs.

Company contacts: -

For communication queries regarding Abacus Medicine Pharma Services, please contact:

Andrew Waiton, Senior Marketing Consultant
Email: andrew.waiton@abacusmedicine.com
Phone: + 44 7810 265 076
www.abacusmedicinepharmaservices.com

For local information regarding the Austrian market, please contact:

Abacus Medicine Austria GmbH
1140 Wien, Goldschlagstraße 172/6/3
E-Mail: meinservice@abacusmedicine.at
Phone: +43 1 26 50 642